Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RU 28965

Known as: RU-28965, RU28965 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
The in vitro susceptibility of Mycobacterium avium to RU-28965 alone and in combination with rifampin, isoniazid, and… Expand
Is this relevant?
1987
1987
The in vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic RU-28965, alone and in combination with… Expand
Is this relevant?
1987
1987
The minimal inhibitory concentrations of macrolide antibiotics against staphylococci, streptococci and Haemophilus influenzae… Expand
Is this relevant?
1987
1987
The in vitro activity of erythromycin and RU-28965 (a novel macrolide antimicrobial with improved pharmacokinetics) was… Expand
Is this relevant?
1986
1986
Roxithromycin (RU 28965), an ether oxime derivative of erythromycin, protected mice against a lethal infection with the virulent… Expand
  • table 1
Is this relevant?
1986
1986
The activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly… Expand
Is this relevant?
1986
1986
The in vitro effects of RU 28965 (roxithromycin), a new semisynthetic macrolide, on human neutrophil activity were compared with… Expand
Is this relevant?
1985
1985
The in vitro activity of drugs currently used in the treatment of diarrhea against 595 enteropathogens from worldwide sources was… Expand
Is this relevant?
1984
1984
RU 28965, a novel macrolide antibiotic, inhibited most gram-positive species at concentrations similar to that of erythromycin… Expand
Is this relevant?
1983
1983
Three new macrolide drugs (RU28965, RU29065, and RU29702) were compared in vitro with erythromycin and five other orally… Expand
Is this relevant?